Long-acting insulin analogues were developed to reduce the risk of hypoglycaemia, especially nocturnal hypoglycaemia, producing greater patient convenience through reducing the number of injections (Pedersen-Bjergaard et al., 2014; Rys et al., 2015; Godman et al., 2021a; Chan et al., 2021; Tricco et al., 2021). The gene discussed is INS; the disease is Hypoglycemia.